Get the Stockscreener App
3.27
0.28%
-0.0092
Eupraxia Pharmaceuticals Inc stock is traded at $3.27, with a volume of 5,053.
It is down -0.28% in the last 24 hours and down -19.26% over the past month.
See More
Previous Close:
$3.2792
Open:
$3.15
24h Volume:
5,053
Relative Volume:
0.37
Market Cap:
$117.56M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-4.2468
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
-3.25%
1M Performance:
-19.26%
6M Performance:
+23.86%
1Y Performance:
+0.00%
1-Day Range:
$3.15
$3.27
1-Week Range:
$3.10
$3.45
52-Week Range:
$2.20
$4.48
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
3.27 | 117.56M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
(EPRX) Stock Market Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on Monday - Defense World
When (EPRX) Moves Investors should Listen (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress - MSN
Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation - Yahoo Finance
Learn to Evaluate (EPRX) using the Charts (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals files report with SEC - Investing.com India
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - Weekly Voice
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results -March 20, 2025 at 05:38 pm EDT - MarketScreener
(EPRX) Equity Market Report (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1.7% – What’s Next? - Defense World
(EPRX) Optimized Trading Opportunities (EPRX:CA) - Stock Traders Daily
(EPRX) Proactive Strategies (EPRX:CA) - Stock Traders Daily
How to Take Advantage of moves in (EPRX) (EPRX:CA) - Stock Traders Daily
(EPRX) Daily Stock Insights (EPRX:CA) - Stock Traders Daily
(EPRX) Stock Evaluation Report (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals is undervalued, Research Capital says - Cantech Letter
Eupraxia reports progress in EoE drug trial with promising results By Investing.com - Investing.com Canada
Medicenna Therapeutics Corp. - Baystreet.ca
Dye & Durham Limited - Baystreet.ca
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Eupraxia Pharmaceuticals Shares Rise on Positive Drug Trial Data - MarketWatch
Eupraxia Pharmaceuticals Reports Latest Updates - Investing.com
Eupraxia Pharmaceuticals Reports Latest Updates By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals Inc. Announces Additional Positive Clinical Data from its Ongoing RESOLVE Phase 1b/2a Trial Evaluating EP-104GI for Treatment of Eosinophilic Esophagitis - Marketscreener.com
Eupraxia Pharmaceuticals Reports Promising Trial Results for Eosinophilic Esophagitis Treatment - TipRanks
Eupraxia reports progress in EoE drug trial with promising results - Investing.com India
Eupraxia Pharmaceuticals Brief: Announcing "Positive" Data From RESOLVE Phase 1b/2a Trial Of EP-104GI For Treatment Of Eosinophilic Esophagitis - Marketscreener.com
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - The Globe and Mail
Eupraxia's EoE Drug Achieves 94% Reduction in Key Inflammatory Markers Without Steroid Side Effects - StockTitan
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Research Coverage Started at Craig Hallum - Defense World
Craig-Hallum starts Eupraxia at Buy, sees ‘significant upside’ potential - Yahoo Finance
Craig-Hallum sets $12 target for Eupraxia stock, rates it a Buy - Investing.com Australia
Craig-Hallum sets $12 target for Eupraxia stock, rates it a Buy By Investing.com - Investing.com South Africa
Top Premarket Decliners -February 21, 2025 at 07:50 am EST - Marketscreener.com
Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Declines By 6.0% - Defense World
Propel Holdings Inc. - Baystreet.ca
Eupraxia Pharmaceuticals appoints new CFO By Investing.com - Investing.com Nigeria
EPRXEupraxia Pharmac Latest Stock News & Market Updates - Stock Titan
Exco Technologies Limited - Baystreet.ca
Eupraxia Appoints Alex Rothwell To Succeed Bruce Cousins As CFO - Nasdaq
Eupraxia Pharmaceuticals Announces CFO Succession - GuruFocus.com
Eupraxia Pharmaceuticals Announces CFO Succession Amid Strategic Advancements - TipRanks
Eupraxia Pharmaceuticals appoints new CFO - Investing.com
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):